Intracerebroventricular SynCav1 gene delivery improved motor measures in ALS mice
Original source
i.c.v. delivery of AAV9-synapsin-promoted caveolin-1 attenuates neuromuscular deficits and neuromuscular degeneration in hSOD1G93A mice. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Mouse
Population inferred from the title and abstract by Compass.
AAV9-SynCav1, a gene-delivery treatment carrying caveolin-1, was given into the brain ventricles of hSOD1G93A mice. Treated male mice showed better running-wheel performance and motor-evoked potentials, with less motor-neuron degeneration and better diaphragm neuromuscular-junction innervation.
Why this matters
The study supports intracerebroventricular delivery as a way to distribute SynCav1 across parts of the brain and spinal cord in this ALS mouse model. It is an early preclinical finding and does not change treatment for people with ALS.
Limitations and context
This was a primary research study in hSOD1G93A mice, not people. The reported functional findings were in male mice, and the results are preclinical proof of concept; safety, effectiveness and relevance to human ALS have not been established.